Wolfram Samlowski is an Oncology physician. ClinicalTrials.gov lists 5 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
2050 Pinto Ln Ste 200
Las Vegas, NV 891064019
Telephone
702-473-1757Provider last certified this registry record 5 Sept 2025.
Clinical trials
- Culture and Characterization of Circulating Tumor Cells (CTC) in Melanoma and Other Cancers
Sponsor: Wolfram Samlowski
- 5-aza-2-deoxycytidine With Pegylated Interferon-alfa 2B: A Phase I Study With Molecular Correlates
Sponsor: Nevada Cancer Institute
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
35 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Regeneron Healthcare Solutions, Inc.Program year202514 payments$27,755openpaymentsdata.cms.gov ↗
- Merck Sharp & Dohme LLCProgram year20252 payments
- Daiichi Sankyo Inc.Program year202518 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
77.1%PD-1 inhibitor45.5%Nivolumab56%Pembrolizumab44%Part B, office-administered≥30 patientsPD-1/PD-L1 (Programmed cell death protein 1/death ligand 1) inhibitors22.9%Cemiplimab-rwlc100%Part B, office-administered≥12 patients+ 6 more classes in this area
Metabolism & gastrointestinal
11.5%Other antiemetics9.5%Fosaprepitant100%Part B, office-administered≥29 patientsSerotonin-3 Receptor Antagonist1.9%Granisetron hydrochloride50%Palonosetron hcl46%Ondansetron Odt3%Ondansetron Hcl1%Part D + Part B<11 patients+ 1 more class in this area
Blood & clotting
7.4%Erythropoiesis-stimulating Agent7.3%Darbepoetin alfa100%Part B, office-administered≥13 patientsFactor Xa inhibitor0.1%Eliquis58%Xarelto42%Part D<11 patients+ 1 more class in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
2 NIH research awards on record, funded 2006–2008 per NIH RePORTER. The latest:
- Epigenetic Potentiation of Interferon using Decitabine
Nevada Cancer Institute
FY2008$226,328R21CA122270 - Epigenetic Potentiation of Interferon using Decitabine
Nevada Cancer Institute
FY2007$243,677R21CA122270
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Similar KOLs
Other experts from the same institution or the same specialty.
Freddie Bray
Centre National de la Recherche Scientifique
Jacques Ferlay
Centre international de recherche sur le cancer
Hermann Brenner
German Cancer Research Center
Isabelle Soerjomataram
Centre international de recherche sur le cancer
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”